declares having received consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daichii-Sankyo, esanum, Gilead, Ipsen, Eli Lilly, Novartis, Novo Nordisk, Sandoz and Sanofi
Excellent post this captures the exact tension we see daily in personalized / precision medicine
In these cases, semaglutide can provide the additional support needed to help individuals achieve their goals. While only you and your healthcare provider can decide which option is best for your situation, here are some general considerations: Oral semaglutide (Rybelsus) might be better if: You strongly prefer avoiding injections You don't mind a strict morning routine You don't take other morning medications that would interfere with the 30-minute waiting period You're primarily focused on diabetes management Injectable semaglutide (Ozempic/Wegovy) might be better if: You prefer less frequent dosing (once weekly vs
Future research, she added, could investigate the long-term impacts of switching from GLP-1 receptor agonists to phentermine
Mechanism: Most are pure GLP-1 receptor agonists, but tirzepatide is unique in targeting both GLP-1 and GIP receptors
